Tildrakizumab

Tildrakizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetInterleukin 23 (IL23)
Clinical data
Trade namesIlumya
Other namesTildrakizumab-asmn
AHFS/Drugs.comMonograph
MedlinePlusa618026
License data
Pregnancy
category
  • AU: B1
Routes of
administration		Subcutaneous
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6426H9918N1698O2000S46
Molar mass144436.68 g·mol−1

Tildrakizumab, sold under the brand name Ilumya among others, is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders.[4] It is approved for the treatment of adults with moderate-to-severe plaque psoriasis in the United States and in the European Union.[2][3][5]

Tildrakizumab was designed to block interleukin-23 (IL-23), a cytokine that plays a key role in managing the immune system and autoimmune disease.[6][7]

  1. ^ "Summary Basis of Decision (SBD) for Ilumya". Health Canada. 23 October 2014. Retrieved 29 May 2022.
  2. ^ a b "Ilumya- tildrakizumab-asmn injection, solution". DailyMed. 11 April 2024. Retrieved 2 July 2024.
  3. ^ a b "Ilumetri EPAR". European Medicines Agency. 17 September 2018. Retrieved 2 July 2024.
  4. ^ "Statement on a Nonproprietary Name Adopted by the USAN Council—Tildrakizumab", American Medical Association.
  5. ^ "FDA approves Ilumya for plaque psoriasis". National Psoriasis Foundation. 22 March 2018.
  6. ^ Dolgin E (December 2016). "New anti-IL-23 drugs raise hopes for psoriasis plaque clearance". Nature Biotechnology. 34 (12): 1218–1219. doi:10.1038/nbt1216-1218. PMID 27926724. S2CID 205273437.
  7. ^ Galluzzo M, D'adamio S, Bianchi L, Talamonti M (May 2017). "Tildrakizumab for treating psoriasis". Expert Opinion on Biological Therapy. 17 (5): 645–657. doi:10.1080/14712598.2017.1304537. PMID 28271735. S2CID 4041245.